[Selective trabeculoplasty in combination with vasoactive agents in the complex treatment of primary open-angle glaucoma].
The purpose of the present study was to evaluate the efficiency of complex treatment that has pathogenetic effects on the developmental stages of primary open-angle glaucoma (POAG), by activating the trabecular network via selective laser trabeculoplasty (SLT) and by improving microcirculation with the vasodilator Cavinton Forte. Fifty-seven patients aged 48 to 70 years (72 eyes) who had a developed stage of POAG with uncompensated ophthalmotonus were followed up. Group 1 (a study group) comprised 35 patients (42 years) who received complex therapy (the vasodilator Cavinton Forte 10 mg thrice daily for 2 months along with beta-blockers and prostaglandins. Group 2 (a control group) consisted of 22 patients (30 years) who were first only antihypertensive therapy that did not differ from that taken in Group 1. The complex treatment in patients with the uncompensated developed stage of POAG made it possible to reduce opththalmotonus in 80.9% of the patients to 35% after single application of SLT, to lower intraocular pressure stably, to cause easy outflow of intraocular fluid 2 weeks after SLT, to have positive changes in the stereometric parameters in the optic disk and structural alterations in accordance with the GPS classification, and to discontinue topical antihypertensive agents in 14.3% of the patients.
Shaimova
V A
VA
Shaimov
R B
RB
Goloshchapov
K P
KP
D000328:Adult; D000368:Aged; D002121:Calcium Channel Blockers; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D008833:Microcirculation / Q000187:drug effects; D008875:Middle Aged; D013997:Time Factors; D014129:Trabecular Meshwork / Q000098:blood supply / Q000187:drug effects / Q000601:surgery; D014130:Trabeculectomy / Q000379:methods*; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D014748:Vinca Alkaloids / Q000008:administration & dosage / Q000627:therapeutic use*
D002121:Calcium Channel Blockers; D014665:Vasodilator Agents; D014748:Vinca Alkaloids; C013983:vinpocetine